The goal of the pilot study is to determine if a multicenter prospective cohort study of cancer patients with blood clots associated with catheters is feasible. Cancer patients with catheter-related thrombosis treated with one month of anticoagulation will be evaluated for for post-thrombotic syndrome. Laboratory biomarkers will be evaluated as predictors of recurrent thrombosis.
Name: Heparin, Low-Molecular-Weight, or direct oral anticoagulants
Description: Recruitment of 56 patients in 1 year and 80% completion of post-thrombotic syndrome assessments by enrolled patients
Measure: Number of cancer patients enrolled with catheter-related thrombosis treated with 1 month of anticoagulation Time: 1 yearDescription: Obtaining 80% of samples from enrolled patients
Measure: Number of plasma samples obtained for biomarker analysis to predict recurrent venous thrombosis Time: 1 yearDescription: <20% will have incidence of post-thrombotic syndrome 6 months after catheter removal
Measure: Incidence of post-thrombotic syndrome in cancer patients with catheter-related thrombosis treated with 1 month of anticoagulation Time: 6 months after catheter removalDescription: <20% will have incidence of post-thrombotic syndrome 6 months after catheter removal
Measure: Incidence of recurrent thrombosis in cancer patients with catheter-related thrombosis treated with 1 month of anticoagulation Time: 6 months after catheter removalDescription: <20% will have incidence of post-thrombotic syndrome 6 months after catheter removal
Measure: Incidence of major and clinically relevant non-major bleeding in cancer patients with catheter-related thrombosis treated with 1 month of anticoagulation Time: 6 months after catheter removalAllocation: N/A
Single Group Assignment
There are 2 SNPs
- >18 years of age - Platelet count >50,000 - Creatinine clearance >30 ml/min - Ability to provide informed consent Exclusion Criteria: - Underlying medical condition or chemotherapy requiring long-term anticoagulation - Known underlying higher risk thrombophilias including antiphospholipid antibody syndrome, antithrombin, protein C or protein S deficiencies, or homozygosity or compound heterozygosity for prothrombin G20210A or Factor V R506Q mutations. --- G20210A ---
- >18 years of age - Platelet count >50,000 - Creatinine clearance >30 ml/min - Ability to provide informed consent Exclusion Criteria: - Underlying medical condition or chemotherapy requiring long-term anticoagulation - Known underlying higher risk thrombophilias including antiphospholipid antibody syndrome, antithrombin, protein C or protein S deficiencies, or homozygosity or compound heterozygosity for prothrombin G20210A or Factor V R506Q mutations. --- G20210A --- --- R506Q ---